Labelle Lab has been focusing on designing affordable, and effective point of care biosensors. These range from non-invasive sensing such as the tear glucose sensor, to utilizing electrochemical impedance spectroscopy to detect multiple markers simultaneously. Each of these platfroms have made leaps of progress of the last few years. Non-invasive sensors have been funded by BioAccel, Mayo Development Award, and Advanced Tear Diagnostics. Including 5 recent publications, with collaborations with other facilities such as Mayo clinic and Tokyo University of Agriculture and Techonogy. (Japan). A platform capable of multimarker sensing that is rapid and cheap is currently a large need. Labelle lab has implemented the use of electrochemical impedance spectroscopy to detect various biomarkers using an “optimal binding frequency”.
Noninvasive Sensing: The noninvasive POC biosensing has two major project, touch tear, and saliva glucose. The tear project involves using tear fluid to measure various biomarkers and correlating their values to the blood values. The second main approach is using the saliva as the main detection medium. This has been used to measure glucose for diabetes mellitus in people with diabetes.
Multimarker Sensing: This project has the goal of developing a platform sensing technology capable of multimarker detection that is rapid, label free, and accurate. Labelle Lab intends on applying this platform to diabetes, cardiovascular, cancer, organ transplate health, as well as trauma care. Currently we have demonstrated this using HDL/LDL for cardiovascular health, and are working on diabetes and trauma.
These challenges are currently being tackled by various students such as: Chi Lin (PhD), and Mackenzie Honikel (PhD) and many other great lab members!!